The Motley Fool on $HIMS (Nov 10, 2026)
HIMS is a mixed call: quarterly growth jumped to 49%, partly from acquisitions, at a relatively reasonable multiple, and revenue per subscriber rose to $105 from $80 two quarters earlier; but margins keep falling and subscribers fell about 100,000 to 2.79 million as marketing was pulled back, with rising competition and a marketing-dependent model. One view is that it is too difficult and was skipped; another treats near-term noise as irrelevant on a 10-year view and likes its planned US-made peptides.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
him and hers down about 40% in the past month. Did they pivot to uh AI cloud or Yeah, they need to Yeah, they need to do the uh the Allirds pivot. Yeah, that should probably They're hiring a lot of AI people. um just haven't seen that in in their products yet.
Uh but big move down for them today about 18% as we're recording right now.
The earnings report was really interesting because there's a little something for everybody if you are an Nvidia or if you're a hims and hers bull. You can, you know, squint and make the numbers look pretty good.
I'll just show uh show a couple of things that I think investors are going to be interested in. The growth rates. Make sure these are quarterly. Yep. These are quarterly numbers.
So, the growth rate jumps to 49%. So, one of the interesting I I I always like the takeaway from the market, you know, the stock's down significantly, but you're actually seeing the growth rate jump pretty significantly.
Now, this is partly because of acquisitions. They bought Eucalyptus, they bought uh Zava. Eucalyptus is going to be the big addition right here, but you know, that's a that's a pretty darn good growth rate for a company that's trading for a relatively reasonable multiple.
Um, what you may be a little bit more worried about if you are an investor is the fact that margins continue to go down. Now, couple of couple of caveats here and I'll I'll hide my screen just a second as I pull this up, but there is some interesting dynamics with this company specifically with the way that they're going to market.
So they said in their conference call that they are they actually pulled back on the some of their marketing spending in the most recent quarter to kind of hold that off to until the first of the year.
So after the first of the year typically when people go hey you know maybe I want to lose a little bit of weight this year. Uh that's when gym memberships jump. It's also when I think they see a lot of their GP1 in particular sales jump.
Um we're also going to have peptides in the market at that point. They're expecting to launch that later this month. And then TRT, too. So, you've got kind of a wide range of products and they're kind of saying, you know what, we pulled back in our marketing because we want to kind of get our ducks in a row and make sure that we're really hitting the ground running with these new products.
Uh they've also got another partnership with or another product coming from Novo Nordisk. Eli Lily's products just ended up they were on their platform before, but it's a little bit it's like a nicer partnership uh where you're actually getting it from him and hers.
Here's the other thing that uh was a little bit surprising even to me. Um the number of subscribers dropped about 100,000 in the quarter. So 2.89 million a quarter ago, 2.79 million in this most recent quarter.
So this is going to be, you know, this is a relatively high churn business. So you you end that marketing machine and you're going to see the subscriber numbers go down. But offsetting that is a massive jump in revenue per subscriber.
Now $105 per month. Just two quarters ago that was $80. So a $20 increase. This is what you're seeing here is remember GLP1's when they were compounding those it was a relatively inexpensive product.
I think it was $150 a month uh through Hims and Hers was kind of their lowest price point. That got a lot of customers. Then they have they have now transitioned almost entirely to selling branded products.
And the way that the branded products works is, you know, I would I would think that the the margin on the actual branded product itself is pretty pretty low. Like not zero, but close to zero.
So you're buying, let's say, a, you know, Ompic pen or Zepbound or whatever it is. You're paying very little margin for that, but then on top of that, you're paying for what they call a membership.
A little bit like a Costco model. Like Costco makes very little money on the, you know, peanut butter that you buy at Costco. They make money on the membership. That's where their profit comes from.
So that's kind of the analogy there. So you're seeing this in the numbers. They're spending less on marketing. It means less new customers are coming in, but the customers that they have are a much higher price point because they're transitioning to this membership model, but they're also lower margin. So, a lot of different moving parts.
Um, and we'll see, you know, it's it's such an interesting space because it is getting more competitive, but we'll see as we go into the the other thing. Andrew Hub Huber Huberman joining the board of directors and an adviser.
So, he's going to be a big name that we're going to see a lot, too. But anyways, add this all up and the market doesn't like what it sees.
I mean, on the podcaster side of things, from what I read, he got a very good deal. So, yeah, I think it's like $7 million a year for being an adviser, $250,000 in equity, plus a nominal fee for being on the board of directors. So, yeah, it's it's a nice chunk of change.
Yeah, it's not not bad at all. Um, from the business standpoint, I mean, it's still a growing business, but I to me I always felt like this is a business where if they have to market, they have to market the business aggressively in order to continue to grow and to grab more market share and and it's an industry where you have giants that just have way larger budgets than them.
Now, of course, if you continue to grow your own ecosystem and your member base, then and make sure that churn doesn't go up, actually goes down, then I guess that that's that's a good position, but I've just put it in a two too difficult bucket for me, so skipped it.
Here's the other thing that I just want to note. um revenue is going up at a level where even the fact even though the the gross margin from a percentage standpoint is going down, the absolute gross margin is going up.
So just another little note if you're looking at him and hers, it's not all terrible, but I definitely understand the market's reaction going, "Wait a second, subscriber numbers are down.
These are supposed to be going up and to the right. It looks like there's a lot more competition. Now you got lower margins." Um, you know, this is one of those companies that I keep saying over and over again.
If you if you have a 10-year view on the company, this is just noise and you want to listen to what management's doing. I like some of the stuff that they I mean, they're going to be, I think, the only place that's going to make peptides 100% in the US.
Like, they said that they're making their own APIs for BPC57 and things like that. Like, if you want to get into that stuff, this is probably the most reputable place to do it.
7%. Not quite offsetting my HIMS position, but helping just a little.
I think, you know, in my portfolio, I think after this move today, Zeta jumps up to the number one position in my portfolio and now HIMS falls back down. I don't know if it's down to two or three, but uh, but yeah, good good quarter and things are continue to move in the right direction.
What this channel has said about $HIMS
The Motley Fool has 4 calls on this stock; only the adjacent ones are shown.